reports
- Research Team ACF
BrainStorm Cell Therapeutics (BCLI) Update Note 03102024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s). We have stress tested our valuation vs. current global and market events as well as and BCLI’s reverse stock split (R/S) 30 Sept 2024 (to maintain Nasdaq listing). Whilst there are pros and cons – our risk adjusted WACC has increased and NPV reduced, our conservative base case expected dilution assumptions have improved with R/S and Nasdaq compliance and o...
- Research Team ACF
BrainStorm Cell Therapeutics (BCLI) Flash Note 30092024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s). BCLI on Friday confirmed its reverse stock split (R/S) to become effective today 30 Sept 2024 (to maintain Nasdaq listing). Reverse stock splits are often (though not always) an effective mechanism and often lead to an upwards re-rating as psychological market factors come into play. There is also a usual market clearing mechanism that often leads to net s...
- Research Team ACF
BrainStorm Cell Therapeutics (BCLI) Update 23072024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s). Since initiation – CMC FDA questions resolved, commercialization team in place, raised US$ 4m (gross) enabling PIIIb rollout start, signed a CRO and lined up a commercial manufacturer, shortening the BLA timeline. Whilst the US$ 4m raise and new warrants dilution effect has reduced our value range ~5%, it remains well above our >10x return investment hypot...
- Research Team ACF
BrainStorm Cell Therapeutics (BCLI) Initiation 11062024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI, Biotech) is focused on developing autologous mesenchymal stem cell (MSC) therapies for the treatment of neurodegenerative diseases (NDDs) – BCLI’s primary target is the fatal amyotrophic lateral sclerosis (ALS/MND/Lou Gehrig’s). Post hoc analysis of BCLI’s PIII trial data shows BCLI’s NurOwn® (debamestrocel, MSC-NTF), has statistically significant clinical effects on early-stage ALS sufferers and that placebo trialists deteriorate faster. Peer rev...
- Research Team ACF
Regenerative Healthcare - Stem Cells & ALS Thematic 10062024
Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...
NOVN NOVARTIS AG
CG3 CELGENE CORPORATION
QURE UNIQURE NV
MRK MERCK & CO. INC.
JNJ JOHNSON & JOHNSON
GILD GILEAD SCIENCES INC.
CYTK CYTOKINETICS INCORPORATED
BMY BRISTOL-MYERS SQUIBB COMPANY
BIIB BIOGEN INC.
BCLI BRAINSTORM CELL THERAPEUTICS
SAN SANOFI
4523 EISAI CO. LTD.
IONS IONIS PHARMACEUTICALS INC.
WVE WAVE LIFE SCIENCES
PFE PFIZER INC.
ABBV ABBVIE INC.
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
NOVO NOVO NORDISK A/S-B
- Research Team ACF
BrainStorm Cell Therapeutics Inc Core Investment Case 13032024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) is a biotechnology company focused on developing autologous mesenchymal stem cell (MSC) therapies for the treatment of neurodegenerative diseases – BCLI’s primary target is the fatal amyotrophic lateral sclerosis (ALS/MND/Lou Gehrig’s). BCLI’s’s proprietary technology platform, NurOwnTM, stimulates Mesenchymal Stem Cells to emit neurotrophic factors (MSC-NTF), which promote the survival of neurons across multiple disease states.
Catalent und BrainStorm Cell Therapeutics geben Partnerschaft zur Hers...
Catalent und BrainStorm Cell Therapeutics geben Partnerschaft zur Herstellung von NurOwn®, einer auf mesenchymalen Stammzellen beruhenden Therapie, bekannt SOMERSET, N.J. und NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), der weltweit führende Anbieter von modernen Verabreichungstechnologien, Entwicklungs- und Fertigungslösungen für Arzneimittel, Biologika, Zell- und Gentherapien sowie Produkte im Bereich Verbrauchergesundheit, und BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), ein führender Entwickler von zellulären Therapien für die Behandlung neurodegenerativer E...
Catalent et BrainStorm Cell Therapeutics annoncent un partenariat pour...
Catalent et BrainStorm Cell Therapeutics annoncent un partenariat pour la conception de la plateforme de thérapie par cellules souches mésenchymateuses NurOwn® SOMERSET, N.J.et NEW YORK, 23 oct. 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE : CTLT), le plus grand fournisseur mondial de solutions de fabrication, de développement et de technologies d'administration de médicaments, de produits biologiques, de thérapies cellulaires et génétiques et de produits de santé grand public, et BrainStorm Cell Therapeutics Inc. (NASDAQ : BCLI), un développeur de premier plan de thérapies cellulaires pour le...
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the...
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn® SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced an agreement for the manufacture of NurOwn®, BrainS...
BrainStorm to Present at Scientific Conferences in September
BrainStorm to Present at Scientific Conferences in September Advanced Therapies & Expo 2020 on September 9 CIRM 2020 Grantee Meeting on September 14 Collaborations That Transform MS Webinar on September 24 NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it will deliver virtual presentations during Advanced Therapies & Expo 2020, September 9, at the 2020 CIRM Grantee Meeting, September 14, 2020, and at the WuXi Apptec Collaborations That T...
BrainStorm Appoints Pharmaceutical Veteran Anthony Waclawski as Execut...
BrainStorm Appoints Pharmaceutical Veteran Anthony Waclawski as Executive Vice President, Global Head of Regulatory Affairs Company plans to further strengthen its regulatory expertise and capabilities as ALS phase 3 clinical trial nears completion in Q4 NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the appointment of Anthony P. Waclawski, Ph.D. as Executive Vice President, Global Head of Regulatory Affairs. Dr. Waclawski is an industry veter...
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® der...
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS Intratracheal administration of exosomes extracted from MSC’s using NurOwn® technology resulted in statistically significant improvement in multiple lung parameters in a mouse model BrainStorm will discuss results during Q2 corporate earnings call on Wednesday August 5 NEW YORK, July 23, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has ...
BrainStorm Granted SME Status by the European Medicines Agency
BrainStorm Granted SME Status by the European Medicines Agency NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has been granted Small and Medium-Sized Enterprise (SME) status by the . The newly granted SME status allows BrainStorm to participate in significant financial incentives that include a 90% to 100% EMA fee reduction for scientific advice, clinical study protocol design, endpoints and statistical considerations, quality inspection...
BrainStorm Announces Financial Results for the First Quarter of 2020 a...
BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update Conference Call and Today at 8:30 a.m. Eastern Time ALS Phase 3 Clinical Trial Remains on Track for Q4’20 Top-line Data Readout NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2020 and recent corporate updates. “While many companies have been greatly hindered by the COVID-19 pandemic, Brainstorm, due to the i...
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Me...
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today a lease agreement with the (“Sourasky) in Tel Aviv, Israel, to produce NurOwn® in three state-of-the-art cleanrooms. The new facility will significantly increase the Company’s capacity to manufacture and ship its product into the European Union and the local ...
BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in...
BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that new data highlighting the immunomodulatory effects of NurOwn® on B and T regulatory function appeared in an online supplement to . The abstract was originally planned for presentation at the recently cancelled 2020 American Academy of Neurology (AAN) annual meeting. In addition to the online supplement, the abstract is also ...
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Resul...
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update Thursday, May 7, 2020, 8:30 a.m. EDT NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc. (), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2020, and provide a corporate update, at 8:30 a.m, Eastern Daylight Time, on Thursday, May 7, 2020. Brain...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.